Baiqu Bio is a high-tech enterprise specializing in the application, consulting and development of cutting-edge research technology in life sciences. It is also an early detection and analysis service organization for comprehensive solutions of metabolomics in China. The company's core team has extensive experience in the field of metabolomics in scientific research services, health testing, and industrial testing. Baiqu Bio focuses on mass spectrometry and metabolic testing, and continues to develop and research on metabolomics product innovation and technology. At present, it has a number of metabolomics patents, masters the core technology in the field of metabolomics, and is proud of the domestic metabolomics detection and analysis field. Achievements. Since its inception, the company's performance has maintained a steady growth momentum for consecutive years and has achieved profitability for six consecutive years.
Prime Lifescience is a developer of a big data platform that focuses on life sciences. The company is dedicated to establishing a health lifecycle big data collaboration network through digital technology innovation and extensive use of artificial intelligence. They offer a digital smart health community, a digital intelligent clinical research accelerator, and a live big data platform as part of their offering.
Sinogen Biopharma is founded with a vision to bridge China's biotech innovation to the US pharma market. The company licenses and develops innovative drugs from China.
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Fremont, California.
PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Basecamp Bio is a cell and gene therapy research and development company that develops cell and gene therapies, regenerative medicine, and immunotherapies.
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Fremont, California.
Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. It was founded in 2010 and headquartered in Cambridge, Massachusetts.
Bioscience provides in vitro diagnostic medical devices and reagents intended to enhance the diagnostic capabilities of healthcare professionals. They offer products that include chemiluminescence, point-of-care testing, and supporting instruments and reagents that enable healthcare organizations to offer enhanced care.
Berry Genomics is the genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietary next-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards. The company was founded in 2011 and is headquartered in San Francisco, California.
Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. It was founded in 2010 and headquartered in Cambridge, Massachusetts.
MicroPoint Bioscience, Inc. (微点生物) is a Chinese company dedicated to biochip research and development. The company offers a product series, Lab On a Chip, which is based on micro-electronic mechanical technologies. MicroPoint Biosciences customizes demanded products and services for customers in areas of human health such as medicine, environmental protection, food safety, scientific research, and other application areas. In the area of medicine, MicroPoint Company's bedside immediate diagnosis chip and examination instrument provides low-cost resolutions for early diagnosis and the process monitoring of vascular diseases, tumors, emergency treatments, and operations.
Berry Genomics is the genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
Bioscience provides in vitro diagnostic medical devices and reagents intended to enhance the diagnostic capabilities of healthcare professionals. They offer products that include chemiluminescence, point-of-care testing, and supporting instruments and reagents that enable healthcare organizations to offer enhanced care.
ARMO BioSciences, Inc. is an immuno-oncology company based in Redwood City, California, focused on developing biologic therapeutics that stimulate the immune system to combat cancer. The company's product pipeline includes several innovative candidates, such as AM0010, a long-acting form of interleukin-10 that enhances immune response, and AM0001, an anti-PD-1 monoclonal antibody targeting various cancers. Other key products in development include an anti-LAG-3 checkpoint inhibitor, AM0015, a recombinant form of interleukin-15, and AM0012, a recombinant interleukin-12. Established in 2010 and formerly known as Targenics, ARMO BioSciences aims to activate and enhance the body's immune response against tumors, thereby improving outcomes for cancer patients. As of mid-2018, it operates as a subsidiary of Eli Lilly and Company.
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.
Sinocelltech is a biotech company that develops and manufactures recombinant proteins, monoclonal antibodies, and vaccines. It has developed platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. The company is driven by a mission to make life-saving biological medicines available to ordinary people with ever-improving process and manufacturing technologies to drive down the cost of product development and production.
Berry Genomics is the genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
MedSci provides strategies, solutions and services to pharmaceutical, biotech and medical device organization and the consumer healthcare industry
BBI Life Sciences Corporation is a prominent investment holding company based in Shanghai, China, specializing in the development, manufacturing, and sale of a wide range of life sciences products and services. The company operates through five segments: DNA Synthesis Products, Genetic Engineering Services, Life Science Research Consumables, Protein and Antibody Related Products and Services, and Third Party Detection. Its offerings include oligonucleotide synthesis and gene synthesis products for molecular biology and medical research, DNA sequencing, gene cloning, and various laboratory consumables. Additionally, BBI provides services related to protein extraction and analysis, as well as custom antibody production. The company serves a diverse clientele that includes universities, research institutes, hospitals, and pharmaceutical firms, both domestically and internationally. BBI Life Sciences has established a strong market presence with its well-recognized brands and is noted for its quality products and competitive pricing. Founded in 2013, BBI Life Sciences has quickly become a leading provider in the life sciences research sector in China.
CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. Their premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. They are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.
Berry Genomics is the genomics company specializing in developing and commercializing technologies for life sciences and clinical applications. Among the clinical applications, the company is dedicated to developing next generation sequencing (NGS) based tests for genetic disease and cancer from preconception to adulthood.
OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs. It strives to fulfill its mission of supplying everything a researcher needs for gene-based research. Through licensing and selling research materials including genes, proteins, and research tools, it enables critical biological research.
Beijing Centre Biology Co., Ltd is a high-technology company specializing in researching, developing, manufacturing and selling animal health care products. Their core products contain natural herbal products、Vaccine, chemical drugs and feed additives.
Founded in 1998, Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since its inauguration, Gan & Lee has been focusing on insulin production. In 1998, Gan & Lee successfully developed the first domestic biosynthetic human insulin, which was evaluated as China’s top 10 scientific and technological breakthroughs by Chinese Academy of Sciences and Engineering. Hitherto Gan & Lee has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin®, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25®, all of which have received high reputation from nationwide clinicians and patients, with outstanding efficacy and safety guarantees.
Beijing Centre Biology Co., Ltd is a high-technology company specializing in researching, developing, manufacturing and selling animal health care products. Their core products contain natural herbal products、Vaccine, chemical drugs and feed additives.
CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. Their premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. They are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.
Founded in 1998, Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since its inauguration, Gan & Lee has been focusing on insulin production. In 1998, Gan & Lee successfully developed the first domestic biosynthetic human insulin, which was evaluated as China’s top 10 scientific and technological breakthroughs by Chinese Academy of Sciences and Engineering. Hitherto Gan & Lee has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin®, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25®, all of which have received high reputation from nationwide clinicians and patients, with outstanding efficacy and safety guarantees.
Sangon Biotech Co. (生工生物) is engaged in the research and development of chemical synthesis of DNA. It is a high-tech Sino-foreign joint venture established in 2003. After ten years of development, Sangon has become a professional biotechnology company that integrates research and development. Chemical synthesis DNA earned reputation for Sangon in the global market. In 2006, Sangon invested 50 million to build a manufacturing and industrial base in Songjiang Industrial Park, which has been put into use. Sangon produces various products such as DNA synthesis, DNA sequencing, Gene Synthesis, peptide synthesis, chemical agents, enzymes, molecular biology kit, cultivation medium, lab consumptive material, and miniature instruments.
Founded in 1998, Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since its inauguration, Gan & Lee has been focusing on insulin production. In 1998, Gan & Lee successfully developed the first domestic biosynthetic human insulin, which was evaluated as China’s top 10 scientific and technological breakthroughs by Chinese Academy of Sciences and Engineering. Hitherto Gan & Lee has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin®, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25®, all of which have received high reputation from nationwide clinicians and patients, with outstanding efficacy and safety guarantees.
CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. Their premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. They are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.
CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. Their premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. They are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.